Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,643Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and ImmunotoxinsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index.

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Open access
Fu, Zhiwen, Li, Shijun, Han, Sifei, Shi, Chen, Zhang, Yu·2022·Signal Transduction and Targeted Therapy

Abstract

Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg ® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreover, over 100 ADC candidates have been investigated in clinical stages at present. This kind of new anti-cancer drugs, known as “biological missiles”, is leading a new era of targeted cancer therapy. Herein, we conducted a review of the history and general mechanism of action of ADCs, and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. Moreover, we also reviewed the approved ADCs and other promising candidates in phase-3 clinical trials and discuss the current challenges and future perspectives for the development of next generations, which provide insights for the research and development of novel cancer therapeutics using ADCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-00947-7

Cites

275 of 275 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Timeline depicting important events in the development and approval of ADC drugs over the past century since the “magic bullet” was proposed by Paul Enrlich 1910. ADC, antibody-drug conjugate; CEA, Carcinoembryonic antigen; ALL, acute lymphoid leukemia; BR96, an antibody binding to Lewis Y; DOX, doxorubicin; FDA, the U.S. Food and Drug Administration
Fig. 1 Timeline depicting important events in the development and approval of ADC drugs over the past century since the “magic bullet” was proposed by Paul Enrlich 1910. ADC, antibody-drug conjugate; CEA, Carcinoembryonic antigen; ALL, acute lymphoid leukemia; BR96, an antibody binding to Lewis Y; DOX, doxorubicin; FDA, the U.S. Food and Drug AdministrationCC BY · PubMed Central
Fig. 2 The structure and characteristic of an ADC drug. The core components including target antigen, antibody, linker, cytotoxic drug along with their key functions are demonstrated.
Fig. 2 The structure and characteristic of an ADC drug. The core components including target antigen, antibody, linker, cytotoxic drug along with their key functions are demonstrated.CC BY · PubMed Central
Fig. 3 The important target antigens from tumor cells (overexpressed and driver genes) and tumor microenvironment (vasculature and stroma) are used for the development of ADC. Created with BioRender.com
Fig. 3 The important target antigens from tumor cells (overexpressed and driver genes) and tumor microenvironment (vasculature and stroma) are used for the development of ADC. Created with BioRender.comCC BY · PubMed Central
Fig. 4 The overview of the mechanisms of ADC for killing cancer cells via different approaches. Upper-Right: The main core mechanism of action of ADCs; Lower-Left: The antibody component of ADCs engages with immune effector cells to elicit antitumor immunity including CDC, ADCC, and ADCP effects; Lower-Right: The antibody component of ADCs retains its activity profile and can therefore interfere with target function, dampen downstream signaling to inhibit tumor growth. Created with BioRender.com
Fig. 4 The overview of the mechanisms of ADC for killing cancer cells via different approaches. Upper-Right: The main core mechanism of action of ADCs; Lower-Left: The antibody component of ADCs engages with immune effector cells to elicit antitumor immunity including CDC, ADCC, and ADCP effects; Lower-Right: The antibody component of ADCs retains its activity profile and can therefore interfere with target function, dampen downstream signaling to inhibit tumor growth. Created with BioRender.comCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 275 references

Research works printed but not linked: 2

  1. Cortés, J. et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Ann. Oncol. 32, S1287–S1288 (2021). · DOI
  2. Spira, A. et al. OA03.03 Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study. J. Thorac. Oncol. 16, S106–S107 (2021). · DOI

Cited by

See all 1,643

Metadata

Authors
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y.
Affiliations
  • Huazhong University of Science and Technology (CN)
  • China Pharmaceutical University (CN)
  • Wuhan Union Hospital (CN)
Corresponding author
Zhang, Yu
Venue
Signal Transduction and Targeted Therapy
Published
2022-03-22
Volume
7
Issue
1
Pages
93-93
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4220847494
Cited by
1,643
References
275
Citations by year
2026: 374 · 2025: 510 · 2024: 433 · 2023: 283 · 2022: 43
FWCI
54.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82073402)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
antibody-drug conjugates, targeted cancer therapy, monoclonal antibodies, cytotoxic drugs, chemical linkers, mechanism of action, gemtuzumab ozogamicin
MeSH terms
Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, United States, United States Food and Drug Administration, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody drug conjugate: the “biological missile” for targeted cancer therapy. https://app.cochat.ai/papers/10.1038/s41392-022-00947-7
The paper
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-00947-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.